Hospitalpharmacyeuropefeed

Single-dose clesrovimab is well tolerated in infants at increased risk of severe respiratory syncytial virus (RSV) disease, with phase 3 data supporting its use in those who still require protection during a second season.

Prasugrel reduces major adverse cardiovascular events (MACE) compared with ticagrelor and clopidogrel without increasing major bleeding following percutaneous coronary intervention (PCI), according to a large network meta-analysis.

Antiplatelet therapy remains a cornerstone of

Some commonly prescribed antihypertensive drug combinations may be better tolerated than monotherapy, with angiotensin II receptor blocker (ARB)-based regimens associated with the lowest rates of treatment discontinuation due to adverse events, according to a large network meta-analysis of randomised clinical trials.

Although effective therapies are widely availabl...

A phase 3 trial has positioned the investigational RAS(ON) inhibitor daraxonrasib as a potential advance for previously treated metastatic pancreatic cancer. Beyond its clinical significance, pan-RAS inhibition signals a new era of potential therapy and highlights the expanding role of hospital pharmacists in precision oncology, as Dr João Gonçalves PhD explains.

In this expert commentary, Solomon Ahmed Mohammad and Dr Fekade Bruck Sime of The University of Queensland, Australia, discuss how outpatient parenteral antimicrobial therapy programmes in the UK, Europe and beyond are evolving, and explore the multidisciplinary, technological and organisational factors required to support safe, effective and sustainable delivery.